Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGFBP3 | P17936 | 2/20 | 0.47 |
| ▸ | IGFBP5 | P24593 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | KMO | O15229 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Chlorokynurenic Acid SCHEMBL29386783 | 1.00 | IGFBP3 (0.47) | IGFBP3IGFBP5CA1CA2DHODH | |
| 7-Chlorokynurenic Acid SCHEMBL31238955 | 1.00 | IGFBP3 (0.47) | IGFBP3IGFBP5CA1CA2DHODH | |
| 7-Chlorokynurenic Acid SCHEMBL20770380 | 0.98 | IGFBP3 (0.46) | IGFBP3IGFBP5CA1CA2DHODH | |
| SCHEMBL1305232 | 0.88 | ALDH1A1 (0.49) | IGFBP3IGFBP5CA1CA2DHODH | |
| SCHEMBL14514060 | 0.85 | GRM2 (0.53) | KMOKMT2APOLB | |
| SCHEMBL12349843 | 0.85 | KMT2A (0.52) | DHODHKMOKMT2APOLBALDH1A1 | |
| SCHEMBL15129999 | 0.83 | ALDH1A1 (0.51) | IGFBP3CA1CA2DHODHKMO | |
| SCHEMBL2905794 | 0.83 | IGFBP5 (0.46) | IGFBP3IGFBP5CA1CA2ALDH1A1 | |
| SCHEMBL8337206 | 0.82 | DHODH (0.43) | IGFBP3IGFBP5DHODHKMOKMT2A | |
| SCHEMBL2904899 | 0.81 | EGFR (0.46) | KMT2APHLPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4629989-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | Freedom Biosciences, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| US-20240350433-A1 | TREATMENT COMPOSITIONS AND METHODS | UNIV YALE (US) | 2024-10-24 | — | — | US | claimed |
| WO-2024123935-A2 | TREATMENT OR PREVENTION OF DEPRESSIVE DISORDERS THROUGH COMBINATION THERAPY | FREEDOM BIOSCIENCES, INC. (US) | 2024-06-13 | — | — | WO | claimed |
| US-20240066003-A1 | NEURODEVELOPMENTAL DISORDER THERAPY | ANAVEX LIFE SCIENCES CORP. (US) | 2024-02-29 | — | — | US | claimed |
| US-20230355596-A1 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | VERSITECH LIMITED (CN) | 2023-11-09 | — | — | US | claimed |
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-11-29 | — | — | US | claimed |
| US-20220354827-A1 | NTRANASAL DANTROLENE ADMINISTRATION FOR TREATMENT OF ALZHEIMER'S DISEASE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2022-11-10 | — | — | US | claimed |
| CN-114828848-A | Intranasal dantrolene administration for the treatment of alzheimer's disease | 宾夕法尼亚大学理事会 | 2022-07-29 | — | — | CN | claimed |
| CN-114225039-A | Antagonist composition and application thereof in preparation of medicine for treating sleep disorder and mental disease | 中国科学院深圳先进技术研究院 | 2022-03-25 | — | — | CN | claimed |
| CN-112933073-A | Dosage forms and therapeutic uses of L-4-chlorokynurenine | 维斯塔津治疗公司 | 2021-06-11 | — | — | CN | claimed |
| WO-2002070499-A2 | PRODRUGS DERIVATIVES OF THE ASCORBIC ACID SUITABLE TO THE PASSAGE OF THE HEMATOENCEPHALIC BARRIER | UNIVERSITA'DEGLI STUDI DI FERRARA (IT) | 2002-09-12 | — | — | WO | claimed |
| US-20020007067-A1 | Noncatalyzed synthesis of 4-hydroxyquinolines and/or tautomers thereof | RHODIA CHIMIE (FR) | 2002-01-17 | — | — | US | claimed |
| EP-1151295-A1 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | Cytovia, Inc. (US) | 2001-11-07 | — | — | EP | claimed |
| WO-2000045165-A1 | METHODS OF IDENTIFYING THERAPEUTICALLY EFFECTIVE ANTINEOPLASTIC AGENTS WITH CULTURED CELLS HAVING INTACT CELL MEMBRANES AND CORRESPONDING PRODUCTS | CYTOVIA, INC. (US) | 2000-08-03 | — | — | WO | claimed |
| EP-1002535-A1 | New use of glutamate antagonists for the treatment of cancer | Ikonomidou, Hrissanthi (DE) | 2000-05-24 | — | — | EP | claimed |
| WO-1998010757-A9 | THE USE OF FUNCTIONAL N-METHYL-D-ASPARTATE ANTAGONISTS TO AMELIORATE OR PREVENT AMINOGLYCOSIDE-INDUCED OTOTOXICITY | — | 1998-07-23 | — | — | WO | claimed |
| WO-1998010757-A2 | THE USE OF FUNCTIONAL N-METHYL-D-ASPARTATE ANTAGONISTS TO AMELIORATE OR PREVENT AMINOGLYCOSIDE-INDUCED OTOTOXICITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-03-19 | — | — | WO | claimed |
| EP-0678021-A1 | METHODS FOR THE IMPROVEMENT OF COGNITION WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE NMDA RECEPTOR COMPLEX | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-10-25 | — | — | EP | claimed |
| WO-1994015598-A2 | METHODS FOR THE IMPROVEMENT OF COGNITION WITH FUNCTIONAL ANTAGONISTS OF THE GLYCINE NMDA RECEPTOR COMPLEX | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, ASREPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1994-07-21 | — | — | WO | claimed |
| WO-1992021340-A1 | A METHOD OF TREATING INFECTIOUS ENCEPHALITIS OF VIRAL OR BACTERIAL, OR PARASITIC PATHOGENESIS | UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 1992-12-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510929-B2 | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids | GABRB2, GABRA4, GABRB1 | IGFBP3 3777/4885IGFBP5 3481/4885CA1 389/4885 |
| US-20230355596-A1 | COMPOSITIONS AND METHODS OF USING NMDAR INHIBITORS AND KINASE INHIBITORS TO TREAT LIVER CANCER | GRIN1, GRIN3A, GRIN3B | IGFBP3 3623/4885IGFBP5 4033/4885CA1 116/4885 |
| US-20020007067-A1 | Noncatalyzed synthesis of 4-hydroxyquinolines and/or tautomers thereof | HAAO, HPD, HAO2 | IGFBP3 4860/4885IGFBP5 4659/4885CA1 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.